Therefore, we aimed to investigate the group of IPF patients treated with antifibrotic drugs (either pirfenidone or nintedanib) to determine if the presence of minor allele of the MUC5B gene influenced the treatment outcome and survival. Here, MUC5B is linked to idiopathic pulmonary fibrosis.